Open house discount agreement Brodalumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 523 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Brodalumab, ATC L04AC12

60/100

Score d'opportunité

PromisingLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

Lack of estimated value or volume – unknown revenue potential.

Submission requirements (paper vs electronic) may cause delays if not followed precisely.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Strong opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Mar 2028
Supply of pharmaceutical products containing Brodalumab (ATC L04AC12)
Discount agreements under §130c SGB V with AOK Bayern

Afficher le résumé complet

This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Brodalumab (ATC L04AC12). All qualified pharmaceutical companies can join on identical terms. Contracts run from earliest 01.04.2026 to 31.03.2028, with rolling monthly entry. No estimated value provided. The notice is published for transparency but does not constitute a competitive tender.

Risques

Lack of estimated value or volume – unknown revenue potential.

Submission requirements (paper vs electronic) may cause delays if not followed precisely.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

Only pharmaceutical companies are eligible as potential contract partners.

Administrative

Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
Submission of signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; no selection is made under the open-house model.

Acheteur

Nom

AOK Bayern - Die Gesundheitskasse

Localisation

München, DEU

[email protected]

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreement Brodalumab

Non-exclusive discount agreements for pharmaceutical products containing Brodalumab (ATC L04AC12) with AOK Bayern. Open to all interested pharmaceutical companies meeting eligibility criteria. Contracts are identical and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; no selection is made under the open-house model.

Date limite

Deadline Feb 03, 2028

Détails de la procédure

Date de publication: 15 Feb 2026
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 107840-2026

Documents (2)

Document de consultation 1 Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3